A Double-Blind, Controlled Phase 2b Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Apr 2018
At a glance
- Drugs SB 623 (Primary)
- Indications Stroke
- Focus Therapeutic Use
- Acronyms ACTISSIMA
- Sponsors SanBio
- 01 Apr 2018 According to a SanBio media release, results are expected to be published by July 2019 after 12-month follow-up period.
- 16 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 05 Jul 2017 According to a SanBio Inc. media release, enrollment in this trial is expected to be complete in March 2018 and results are expected in 2019.